Xceleron and JCL Bioassay Partner in Early-Stage Clinical Investigations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Xceleron and JCL Bioassay Partner in Early-Stage Clinical Investigations



Xceleron, a provider of bioanalytical accelerator mass spectrometry (AMS) services for accelerated early drug development, has entered into a partnership with JCL Bioassay, a Japanese CRO and provider of bioassay services for preclinical and clinical developments. The partnership seeks to offer drug developers access to a range of sensitive and robust analytical platforms for early clinical development across Asia, Europe, and North America.

"This partnership emphasizes the crucial role of contemporary analytical platforms in driving down the cost of drug development. Whether in Phase 0 or enriched Phase I, we can confidently provide critical pharmacokinetic and pharmacodynamic information before Phase II," said Dr Michael Butler, CEO of Xceleron, in a press statement.

Over the years, Phase 0 and enriched Phase 1 studies have been used successfully in to investigate a range of developmental endpoints such as the presence of drug at tissues or cells of interest, absolute bioavailability, and human metabolism. These studies when conducted early in drug development allow confident decision-making that offers a cost-effective alternative when compared to later stages of clinical development.

More than 100 analytical methods for Phase 0 and enriched Phase I investigations have been developed between Xceleron and JCL Bioassay. Both companies recently built laboratories that are equipped and staffed specifically for the purpose of conducting ultra-low level analyses under good laboratory practice (GLP) and good clinical practice (GCP) conditions. This partnership will provide access to clinical design expertise as well as appropriate analytical platforms for the purpose of early clinical investigation.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here